MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset

C. Kwan, I. Frouni, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

Meeting: 2022 International Congress

Abstract Number: 672

Keywords: Dyskinesias, Glutamate, Parkinson’s

Category: Neuropharmacology

Objective: To determine the effect of positive allosteric modulation of the metabotropic glutamate type 2 (mGlu2) receptor in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset using a low dose L-3,4-dihydroxyphenylalanine (L-DOPA) paradigm.

Background: Activation of mGlu2 receptors dampens glutamate release in cortico-striatal synapses, which may alleviate the abnormal glutamatergic transmission that occurs in Parkinson’s disease (PD). Indeed, we demonstrated that mGlu2 receptor activation enhances the anti-parkinsonian action of a therapeutic dose of L-DOPA. However, it is unclear whether this benefit extends to a low dose L-DOPA paradigm that sub-optimally reduces parkinsonism. To this end, we administered the mGlu2 positive allosteric modulator (PAM) biphenylindanone (BINA) to MPTP-lesioned marmosets and assessed its effects on parkinsonism, dyskinesia, and psychosis-like behaviours (PLBs).

Method: Six common marmosets (Callithrix jacchus, 3F and 3M) were rendered parkinsonian by MPTP injection. In a within-subjects design, animals were administered L-DOPA/benserazide 7.5/1.875 mg/kg in combination with BINA (vehicle, 0.1, 1, and 10 mg/kg). The severity of parkinsonism, dyskinesia, and PLBs was assessed post hoc.

Results: When BINA 1 and 10 mg/kg were added to L-DOPA, global parkinsonism severity was reduced by 38% (P < 0.0001) and 53% (P < 0.001). This effect was accompanied by a 52% and 60% increase in on-time (both P < 0.001). Whereas the combination of BINA 10 mg/kg and L-DOPA led to a 94% and 93% reduction in global dyskinesia and PLBs severity (both P < 0.01), lower doses failed to achieve statistical significance.

Conclusion: Our results suggest that mGlu2 positive allosteric modulation may enhance the anti-parkinsonian benefit conferred by low dose L-DOPA. Compounds with this activity may be useful in an L-DOPA-sparing strategy that attempts to provide long-term control of symptoms and quality of life for early stage PD patients.

To cite this abstract in AMA style:

C. Kwan, I. Frouni, S. Nuara, J. Gourdon, P. Huot. The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/the-mglu2-positive-allosteric-modulator-bina-extends-enhances-low-dose-l-dopa-anti-parkinsonian-action-in-the-mptp-lesioned-marmoset/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-mglu2-positive-allosteric-modulator-bina-extends-enhances-low-dose-l-dopa-anti-parkinsonian-action-in-the-mptp-lesioned-marmoset/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley